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NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLERO-
SIS
Burt, R.K.1, Oyama, Y.1, Statkute, L.1, Quigley, K.1, Weppner, C.1,
Krosnjar, N.1, Verda, L.1 Division of Immunotherpay, Department of
Medicine, Northwestern University Feinberg School of Medicine, Chi-
cago, IL.
We have previously reported that autologous hematopoietic stem
cell transplantation (HSCT) using a cancer-speciﬁc myeloablative
regimen (cyclophosphamide [CY] and total body irradiation) failed
to improve the neurologic disability (EDSS) score or even forestall
progressive neurologic decline in patients with secondary progres-
sive (axonal degenerative) multiple sclerosis. We, therefore, rede-
signed our approach to employ a non-myeloablative lymphoabla-
tive conditioning regimen composed of agents speciﬁcally used to
treat multiple sclerosis (CY and CAMPATH-1H). Patients with
relapsing-remitting (inﬂammatory) multiple sclerosis with pre-
transplant EDSS of 2.0 to 6.0 were candidates for our study.
Nineteen patients were treated. Peripheral blood stem cells were
mobilized with intravenous (IV) CY 2g/m2 and subcutaneous G-
CSF 10 mcg/kg/day. Conditioning regimen consisted of IV CY
200 mg/kg and CAMPATH-1H 20 mg. Mobilization and condi-
tioning regimens were well tolerated. No patient had either an
early or late infection, only half of the patients had a neutropenic
fever. Of those who developed fever during the transplant, fever
lasted less than 24 hours and was related to CAMPATH-1H or
stem cell infusion. One-half of the patients never required RBC
transfusion and one quarter never required a platelet transfusion.
The mean day of white blood cell engraftment was day 8. The
mean day of hospital discharge was day 10. CD4 recovery oc-
curred by 6 months. The EDSS neurologic rating scale that varies
from 0 (normal) to 10 (dead from neurologic disease) is evaluated
after HSCT every 6 months twice then annually. In 15 patients
who were followed for 6 or more months, the EDSS has improved
by at least one point in the majority (8 patients), remained un-
changed in 6 and deteriorated in only 1. A randomized trial, the
Multiple Sclerosis International Stem Cell Transplant (MIST) trial
comparing autologous non-myeloablative HSCT to continued
standard therapy for patients with refractory relapsing-remitting
MS is currently registering patients. Reference: Burt RK, Cohen
BA, Russell E, Spero K, Joshi, A Oyama, Y, Karpus WJ, Luo K,
Jovanovic, J, Traynor AE, Burns, WH. Hematopoietic stem cell
transplantation for progressive multiple sclerosis: failure of intense
immune suppression to prevent disease progression in patients
with high disability scores. Blood, 102(7):2373-8, 2003.
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AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
REFRACTORY CROHN’S DISEASE, THE SUMMARY OF PHASE I TRIAL
Oyama, Y.1, Craig, R.M.1, Quigley, K.1, Statkute, L.1, Burt, R.K.1
Division of Immunotherapy, Department of Medicine, Northwestern
University Feinberg School of Meidicine, Chicago, IL.
Background: Crohn’s disease (CD) is an immunologically me-
diated inﬂammatory disease of the gastrointestinal tract. In theory,
immune ablation followed by autologous hematopoietic stem cell
transplantation (HSCT) can induce disease remission by destroy-
ing old and reconstituting a new immune system. Methods: We
conducted a phase I autologous non-myeloablative immunoabla-
tive HSCT trial in 17 patients with severe refractory CD. Patients
were less than 60 years old with a Crohn’s Disease Activity Index
(CDAI) of 250–400 or Craig Crohn’s Severity Index (CCSI) of
17 despite conventional therapy including inﬂiximab. Peripheral
blood stem cells were mobilized with intravenous (IV) cyclophos-
phamide (CY) 2g/m2 and subcutaneous G-CSF 10 mcg/kg/day.
The immunoablative conditioning regimen consisted of 200 mg/kg
IV CY, and 90 mg/kg IV equine antithymocyte globulin. The graft
was CD34 enriched. Results: There was no treatment related
mortality. The procedure was well tolerated. Anticipated neutro-
penic fever, nausea, vomiting, diarrhea, and anorexia were common
and responded well to medical therapy. The median days for
neutrophil and platelet engraftment were 9 (range 7–11) and 9
(range 8–18, three patients never below 20 K/ul), respectively. The
median infused CD34 and CD3 cell counts were 4.83 106/kg
(range 1.73–24.88  106/kg) and 0.56  104/kg (range 0.0–3.09 
104/kg), respectively. Pre-transplant median CDAI and CCSI were
282 (range 101–358) and 24 (range 18–33). After the transplant,
symptoms and CDAI/CCSI tended to improve quickly and dra-
matically, and radiographic and colonoscopy ﬁndings have been
improving gradually over months to years following HSCT. For
patients with 	6 months follow up, 12 out of 15 patients entered
sustained disease remission deﬁned by a CDAI 150 or reduction
of a CCSI 10 after median follow-up of 29 (range 11–48)
months. Conclusions: Autologous HSCT has a marked durable
salutary effect on CD activity and is a safe intervention for patients
with refractory Crohn’s disease. A randomized study (KISS trial:
C[K]rohn’s Immune Suppression vs Stem Cell Transplant) com-
paring autologous immunoablative HSCT to standard therapy is
now enrolling patients.
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AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR DIFFUSE SCLERODERMA
Oyama, Y.1, Statkute, L.1, Barr, W.G.1, Krosnjar, N.1, Yaung, K.1,
Weppner, C.1, Burt, R.K.1 Div. of Immunotherapy, Dept. of Medicine,
Northwestern University Feinberg School of Medicine, Chicago, IL.
Patients with diffuse cutaneous scleroderma with visceral in-
volvement have an overall 10-year survival of 35–68%. There is no
known therapy that is able to alter the natural course of the disease.
Here we report outcomes of autologous HSCT phase I study
utilizing non-myeloablative lymphoablative conditioning regimen.
Nine patients with diffuse scleroderma and poor clinical features
were enrolled. Candidates were less than 65 years old and had
either Rodnan skin score of more than 14 or lung diffusion capacity
of carbon monoxide (DLCO) less than 80%, interstitial lung dis-
ease, elevated ESR, renal involvement, or abnormal electrocardio-
gram. Patients with pulmonary hypertension (pulmonary artery
systolic pressure 	45 mmHg) were excluded. Peripheral blood
stem cells were mobilized with intravenous (IV) cyclophosphamide
(CY) 2g/m2 and subcutaneous granulocyte colony-stimulating fac-
tor 10 mcg/kg daily. The graft was not manipulated. The condi-
tioning regimen consisted of CY 200 mg/kg and rabbit antithymo-
cyte globulin (rATG) 7.5 mg/kg. The procedure was well
tolerated. Anticipated cytopenias, neutropenic fever, and mild ﬂuid
overload were easily controlled. White blood cells and platelets
both engrafted on average day 8 (range days 7–9 and days 0–10,
respectively). The median numbers of infused CD34 and CD3
cells were 8.31  106/kg (range 2.35–14.7  106/kg) and 2.03 
108/kg (range 0.41–6.83  108/kg), respectively. We observed a
marked improvement of skin score in all subjects, whereas cardiac
function (ejection fraction, pulmonary artery systolic pressure),
pulmonary function (DLCO) and renal function (creatinine) re-
mained stable. One patient with advanced disease and poor per-
formance status died 2 years after the transplant from progressive
disease. Two patients developed recurrence of skin tightness with-
out compromising organ function, however, with institution of
mycophenolate mofetil both showed gradual improvement of skin
scores. After median follow-up of 20 (range 5–32) months, the
overall survival is 89% (8 out of 9 patients) and progression-free
survival with continuing improvement is 67% (6 out of 9 patients).
Autologous HSCT with CY/rATG conditioning regimen is safe
and effective. A randomized study (ASSIST: American Sclero-
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derma Stem Cell vs Immune Suppression Trial), comparing
HSCT to IV pulse CY is now enrolling patients.
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LONG TERM REMISSION IN SEVERE AND REFRACTORY LUPUS (SLE)
AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Arnold, R.1, Massenkeil, G.1, Tamm, I.1, Alexander, T.2, Thiel, A.3,
Radbruch, A.3, Hiepe, F.2 1. Department of Internal Medicine, Hema-
tology/Oncology, Charite´ University Medicine Berlin, Berlin, Germany;
2. Department of Internal Medicine, Rheumatology, Charite´ University
Medicine Berlin, Berlin, Germany; 3. German Rheumatism Research
Centre, Berlin, Germany.
The concept of autologous stem cell transplantation (ASCT) is a
resetting of the immune system. High dose chemotherapy and
immune ablation destroys the immune system (autoreactivity) of
the patient followed by a T cell depleted stem cell transplant with
development of a tolerant immune system. Seven patients (age
19–48 years) with life threatening SLE characterized by severe
organ involvement with persistent active disease despite treatment
with standard immunosuppressive drugs were treated in the Berlin
phase I/II trial since 1998 with a median follow up of 55 (8–90)
months. Treatment includes mobilization of hematopoietic stem
cells with cyclophosphamide (CY) 2 g/m2 and G-CSF (10 ug/kg/
day), leukapheresis and enrichment of CD34 cells, conditioning
with CY 200 mg/kg and rabbit antithymocyte globuline (ATG) 90
mg/kg followed by ASCT. Clinical and serological remission could
be achieved in 7/7 patients. One of 7 patients died due to cerebral
aspergillosis on d  90, 1 patient had a ﬂare at 17 months and died
due to uncontrolled SLE 36 months post ASCT. At the time of
ﬂare change of autoantibody proﬁle occurred and naive Th-cells
and naive B-cells declined compared to the remission patients. Five
patients are alive in clinical remission. These patients are autoan-
tibody negative and no autoreactive Th-cells directed to nucleo-
some could be detected after ASCT. One of these patients gave
birth to a healthy boy 35 months post ASCT. Open questions in
ASCT for treatment of SLE are: Is TRM associated with stage of
disease at ASCT/intensive pretreatment? Why do some patients
relapse? Methods of prevention of relapse after ASCT? In Ger-
many, a multicenter clinical trial protocol is initiated to answer
these questions.
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VIRAL INFECTIONS DURING CD34 CELLS PURIFIED AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREAT-
MENT OF REFRACTORY AUTOIMMUNE DISEASES
Nagafuji, K.1, Tsukamoto, H.1, Numata, A.1, Miyamoto, T.2,
Harada, M.1 1. First Department of Internal Medicine, Kyushu Uni-
versity Hospital, Fukuoka, Japan; Center for Cellular and Molecular
Medicine, Kyushu University Hospital, Fukuoka, Japan.
Aims: We retrospectively analyzed viral infections during
CD34 cells autologous peripheral blood stem cell transplantation
(PBSCT) for the treatment of refractory autoimmune diseases
(AD). Materials and Methods: 9 cases of systemic sclerosis (SSc)
with interstitial pneumonia(IP),1 case of amyopathic dermatomy-
ositis (ADM) with IP, 1 case of Wegener granulomatosis (WG)
with exophthalmous. Except one SSc patient No. 9, all patients had
been treated with steroid, and were administered with steroid
during peri-transplant period. PBSC were mobilized with cyclo-
phosphamide (CY) 4 g/m2G-CSF, and CD34 cells were puri-
ﬁed with CliniMACS. Pre-transplant conditioning consisted of CY
200 mg/kg. Acyclovir (ACV) 250 mg/day was administered from
day1 to day 35. Result: Before PBSC mobilizations, patient No. 2
with ADM was positive for cytomegalovirus (CMV) antigenemia
and treated with gancyclovir (GCV). After PBSC mobilizations, 3
patients became positive for CMV antigenemia (3/11 27%) treated
with GCV, and 1 patient developed genital herpes simplex virus
infection treated with ACV. After transplantations, 5 out of 11
patients (45%) became positive for CMV antigenemia treated with
GCV. Median day becoming positive for CMV antigenemia was
22.5 days post-transplant ranging 10 to 38 days. Two patients,
No.1 and No. 8 (18%), developed adenoviral hemorrhagic cystitis
(adeno HC) on day 64 and day 33, respectively, treated with
cidofovir (CDV).Discussion: Before transplantations, most of AD
patients had received immunosuppressive therapy. CD34 cells
PBSCT is an immunosuppressive therapy. Thus, during peri-
transplant period, AD patients developed various viral infections.
Infection surveillance and diagnostic work-up, same as with those
used in allogeneic recipients seem to be necessary (Table1).
Patient
No.
Age/
Sex Diseases
Pre-
mobilization
Steroid Tx
Pre-
mobilization
Viral
Infections
Post-
mobilization
Viral
Infections
Post-
transplant
Viral
Infection
1 54/F SSc/IP yes day 38
CMV,
day 64
adeno
HC
2 54/F ADM/IP yes CMV CMV day 21
CMV
3 55/M SSC/IP yes CMV
4 58/M SSc/Ip yes day 10
CMV
5 54/F SSc/IP yes day 24
CMV
6 53/F SSC/IP yes
7 21/M WG yes
8 49/F SSc/IP yes CMV day 31
adeno
HC, day
33 CMV
9 33/F SSc/IP no
10 63/F SSc/IP yes genital HSV
11 61/F SSc/IP yes CMV day 21
CMV
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TARGETED TOTAL MARROW IRRADIATION USING 3D IMAGE GUIDED
TOMOGRAPHIC INTENSITY MODULATED RADIATION THERAPY: AN
ALTERNATIVE TO STANDARD TBI
Wong, J.Y.C.1, Liu, A.1, Schultheiss, T.1, Popplewell, L.1, Stein, A.1,
Rosenthal, J., Forman, S.1, Somlo, G.1 City of Hope Cancer Center,
Duarte, CA.
Purpose: TBI is an important part of many hematopoietic stem
cell transplant (HSCT) conditioning regimens. Dose escalation of
TBI has been difﬁcult due to associated organ toxicities. A method
to deliver a more targeted dose of TBI to sites of greatest tumor
burden is needed to reduce dose to normal organs, reduce toxici-
ties, and permit dose escalation. The purpose of this study was to
evaluate the delivery of targeted myeloablative doses of radiation to
bone and marrow using a recently developed image guided tomo-
graphic intensity modulated radiation therapy delivery system (to-
motherapy). Methods: CT data sets from 3 patients (2 AML and
1 multiple myeloma) were used for dosimetry planning studies to
evaluate two strategies: total marrow irradiation (TMI), where the
target region was deﬁned as the skeletal bone, and total marrow
and lymphoid irradiation (TMLI), where the target regions were
deﬁned as bone, major lymph node chains, liver, spleen, and sanc-
tuary sites, such as brain. Organ doses and dose distributions were
compared to conventional TBI. Results: A 1.7 to 7.5-fold reduc-
tion in median organ dose was observed with TMI and TMLI
compared to conventional TBI. Dose-volume histogram analysis
predicted for the potential to escalate dose to bone and marrow up
to 20 Gy with TMI, while maintaining doses to normal organs at
lower levels compared to conventional TBI to 12 Gy (Table).
Results were similar for the adult and pediatric patients indicating
that this method will be applicable to most patients regardless of
frame size. TMI to 10 Gy was delivered as part of an autologous
tandem transplant regimen to the patient with multiple myeloma.
Clinical results conﬁrmed treatment planning predictions. After
TMI, the patient experienced the expected blood count nadir,
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